Bright Minds Biosciences AI Stock Analysis
Want to see TSE:DRUG full AI Analyst Report?
Bright Minds Biosciences (DRUG) AI Stock Analysis
Bright Minds Biosciences
(CNQX:DRUG)
Overall score is held back primarily by pre-revenue operations, widening losses, and elevated cash burn despite a strong, low-debt balance sheet. Technical indicators are broadly neutral-to-weak, and valuation is constrained by negative earnings and no dividend yield data.
Bright Minds Biosciences (DRUG) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 285.27M
- Dividend Yield
- ―
- Average Volume (3M)
- 1,159
- Price to Earnings (P/E)
- -10.0
- Beta (1Y)
- 1.72
- Revenue Growth
- ―
- EPS Growth
- -117.77%
- Country
- Canada
- Employees
- 26
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Bright Minds Biosciences Business Overview & Revenue Model
Company Description
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epile...
How the Company Makes Money
Bright Minds Biosciences does not appear to have a mature, recurring commercial product revenue base because it is a clinical-stage drug developer. As a result, its ability to generate revenue and fund operations is typically driven by (a) capital ra...
Bright Minds Biosciences Financial Statement Overview
Summary
Balance sheet is strong with minimal debt and substantial equity, but overall financial performance is pressured by pre-revenue operations, widening net losses (TTM about -$27.5M), and increased cash burn (TTM free cash flow about -$20.1M), which elevates funding/dilution risk.
Income Statement
12Very NegativeBalance Sheet
64PositiveCash Flow
18Very Negative| Breakdown | TTM | Sep 2025 | Dec 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -40.10K | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -33.94M | -12.15M | -2.73M | -7.30M | -14.96M | -27.64K |
| Net Income | -24.75M | -12.23M | -2.80M | -7.37M | -14.96M | -8.65M |
Balance Sheet | ||||||
| Total Assets | 310.84M | 84.42M | 6.10M | 6.88M | 12.09M | 20.04M |
| Cash, Cash Equivalents and Short-Term Investments | 308.33M | 82.91M | 5.72M | 6.75M | 11.63M | 19.76M |
| Total Debt | 65.70K | 125.78K | 118.96K | 73.55K | 139.91K | 0 |
| Total Liabilities | 2.55M | 2.38M | 568.26K | 280.86K | 1.54M | 638.57K |
| Stockholders Equity | 308.30M | 82.04M | 5.54M | 6.60M | 10.54M | 19.40M |
Cash Flow | ||||||
| Free Cash Flow | -25.00M | -8.69M | -1.85M | -7.02M | -13.59M | -7.32M |
| Operating Cash Flow | -25.00M | -8.69M | -1.85M | -7.02M | -13.59M | -7.32M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 277.00M | 85.57M | 810.57K | 2.19M | 5.20M | 26.06M |
Bright Minds Biosciences Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DRUG, the sentiment is Negative. The current price of 28.92 is below the 20-day moving average (MA) of 48.82, below the 50-day MA of 66.88, and below the 200-day MA of 96.84, indicating a bearish trend. The MACD of -12.44 indicates Positive momentum. The RSI at 25.25 is Positive, neither overbought nor oversold. The STOCH value of 58.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:DRUG.
Bright Minds Biosciences Risk Analysis
Bright Minds Biosciences disclosed 26 risk factors in its most recent earnings report. Bright Minds Biosciences reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksBright Minds Biosciences Peers Comparison
Overall Rating
TSE:DRUG47Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | CAD 293.58M | -9.97 | -12.56% | ― | ― | -117.77% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:DRUG | Bright Minds Biosciences Inc. | 28.92 | -51.75 | -64.15% | |
| TSE:MYND | Mynd Life Sciences Inc | 0.07 | 0.00 | 0.00% | |
| TSE:IBO | Universal Ibogaine Inc | 0.01 | 0.00 | 0.00% | |
| TSE:MBIO | Mindbio Therapeutics Corp. | 0.07 | -0.81 | -92.61% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: May 21, 2026
